Please use this identifier to cite or link to this item:
|Title:||1D09C3, an mAb specific for MHC-II|
|Citation:||Current Opinion in Molecular Therapeutics, 2008; 10(1):68-74|
|H Zola and A Beare|
|Abstract:||GPC Biotech AG is developing 1D09C3, an anti-MHC class II (HLA-DR) fully human IgG4 antibody isolated by MorphoSys AG (from its HuCAL library of human antibodies), for the potential treatment of hematological malignancies. In December 2006, positive safety data from two phase I clinical trials were reported. Final phase I data were expected in mid-2007; however, no additional data have been released at the time of publication.|
|Keywords:||Animals; Humans; Antibodies, Monoclonal; Histocompatibility Antigens Class II; Drug Evaluation, Preclinical; Antibody Specificity; Structure-Activity Relationship; Clinical Trials as Topic; Patents as Topic; Antibodies, Monoclonal, Humanized; Contraindications|
|Appears in Collections:||Paediatrics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.